Oral Transmucosal Drugs The global oral transmucosal drugs market reached USD 15,005.2 million in 2022 and is projected to witness lucrative growth by reaching up to USD 24,441.4 million by 2030. The market is expected to exhibit a CAGR of 6.4% during the forecast period (2023-2030).
Oraltransmucosal drug administration was an alternative route in end-of-life care and palliative care during the COVID-19 pandemic. Oral transmucosal drug delivery is the systemic distribution of drugs through the mucous membrane of the oral cavity. It is a preferred approach in palliative care compared to other transmucosal drug delivery since it is practical and easy to use. Oral transmucosal drug delivery is a different method for delivering dose formulations for oral or nasal administration.
The increase in incidence of autoimmune disorders, cancer cases, and respiratory issues, technological advancements, and the rise in research activities by the key players about novel oral transmucosal drugs drive the global oral transmucosal drugs market growth.
Oral Transmucosal Drugs Market Dynamics
Increase in the incidence of autoimmune disorders and, cancer to boost the market growth.
Due to the rise in autoimmune illnesses and cancer, the global market for oral transmucosal drugs is likely to grow during the forecast period. Oral cancer and autoimmune illnesses are all diseases that are affecting more and more people worldwide. This increases demand for oral transmucosal medications as they can prevent gastrointestinal degradation and have an immediate start of action.
For instance, according to the CDC's National Diabetes Statistics Report, there are expected to be 37.3 million cases of diabetes worldwide in 2022. About 11.3% of Americans, or 37.3 million people, have diabetes. The 28.5% of the population, or an estimated 28.7 million people, had diabetes, due to which, the demand for transmucosal medications also increases.
Regulatory challenges for the transmucosal drugwill hamperthe globaloral transmucosal drugs marketgrowth.
Regulatory challenges are one of the major factors that can impact the development and commercialization of transmucosal drugs. Some of the regulatory challenges faced by transmucosal drugs include: like all pharmaceutical products, transmucosal drugs must undergo rigorous safety and efficacy testing to gain regulatory approval.
Oral Transmucosal Drugs Market Segment Analysis
The global oral transmucosal drugs market is segmented based on product type, indication, route of administration, distributionchannel and region.
The tablets segment is expected to hold a dominant position in the market over the forecast period.
Tablets segment accounted for the highest market stake, accounting for approximately 47% of the oral transmucosal drugs market share in 2022, owing to the benefits provided by oral transmucosal tablets are including quick absorption, the convenience of administration, less interaction with other medications, and the factors mentioned above helps tablets segment is likely to hold a significant share of the market. For instance, according to a study published in the National Library of Medicine's Journal in August 2021, older adults who take multiple medications frequently experience a decrease in salivary output. The study also revealed that dental risks for older adults who have low resting pH and low stimulated salivary flow rates increase by 63%.
Oral Transmucosal Drugs Market Geographical Share
North America holds a dominant position in the global oral transmucosal drugs market.
North America is estimated to hold about 37% of the totaloral transmucosal drugs market share overthe forecast period.The active regional players and availability of drugs and opioid use disorders helpdrive the market growth in North America. For instance, as per the article published in Stat Pearls in 2022, in the U.S. and throughout the world, opioid use disorder and addiction are still at pandemic levels.
Opioid use disorder (OUD) has affected 3 million American residents and 16 million other people, worldwide. In the U.S., heroin dependence affects more than 500,000 people. The demand for the prescription of opioid drugs is unquenchable in the U.S.
Oral Transmucosal Drugs Market Companies
The major global players in the market include Pfizer Inc., ZIM Laboratories Limited, Aquestive Therapeutics, Inc, IntelGenx Corp, Indivior PLC, C.L.Pharm Co., Ltd, Seoul Pharmaceuticals, Shilpa Therapeutics, Sunovion Pharmaceuticals, Inc, and CURE Pharmaceutical, among others.
Russia Ukraine Conflict Analysis
The Russia-Ukraine conflict is estimated to have a minimal impact on the global oral transmucosal drugs market, owing to the low prevalence and absence of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global oral transmucosal drugs market over the forecast period.
Artificial Intelligence Impact Analysis
Artificial intelligence is expecetd to impact positively for the global oral transmucosal drugsmarket. Artificial neural networks (ANNs), information technology, and wireless communication all play a role in the development of smart medication delivery systems that have the potential to overcome the drawbacks of traditional therapeutic approaches. Devices for regulated drug distribution have more versatility because of the wireless connection.
Key Developments
• On May 21, 2022, ZIM Laboratories Limited announced that AEPMS, the Spanish Agency for Medicine and Healthcare Products, granted marketing authorization to its fully owned European subsidiary, SIA ZIM Laboratories Limited, for its novel product, ""Sildenafil 50 mg"" ODS, in Spain.
• On December 22, 2022, Aquestive Therapeutics, Inc.'s End-of-Phase 2 (EOP2) meeting with the US Food and Drug Administration (""FDA"") for AQST-109 was announced by the company
• On September 28, 2022, Aquestive Therapeutics, Inc., a pharmaceutical company, announced that it entered into a license agreement of supply for Libervant (diazepam) Buccal Film.
Why Purchase the Report?
• To visualize the global oral transmucosal drugs market segmentation based on product type, Indication, end-user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of oral transmucosal drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The global oral transmucosal drugs market report would provide approximately 53 tables, 54 figures, and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies
- 1. Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
- 2. Definition and Overview
- 3. Executive Summary
- 3.1. Snippet by Product Type
- 3.2. Snippet by Indication
- 3.3. Snippet by Route of Administration
- 3.4. Snippet by Distribution Channel
- 3.5. Snippet by Region
- 4. Dynamics
- 4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.1.1. Increase in incidence of autoimmune disorders, respiratory problems, and cancer to boost the market growth
- 4.1.1.2. The increase in medication and pharmacological therapy usage
- 4.1.2. Restraints
- 4.1.2.1. Regulatory challenges for transmucosal drug
- 4.1.3. Opportunity
- 4.1.3.1. Increasing number of research and developments activities
- 4.1.4. Impact Analysis
- 5. Industry Analysis
- 5.1. Porter's Five Forces Analysis
- 5.2. Supply Chain Analysis
- 5.3. Unmet Needs
- 5.4. Regulatory Analysis
- 6. COVID-19 Analysis
- 6.1. Analysis of COVID-19
- 6.1.1. Before COVID-19 Scenario
- 6.1.2. Present COVID-19 Scenario
- 6.1.3. Post COVID-19 or Future Scenario
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During the Pandemic
- 6.5. Manufacturers’ Strategic Initiatives
- 6.6. Conclusion
- 7. Russia-Ukraine Conflict Analysis
- 8. Global Recession Analysis
- 9. Artificial Intelligence Impact Analysis
- 10. By Product Type
- 10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.1.2. Market Attractiveness Index, By Product Type
- 10.2. Tablets
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 10.3. Films
- 10.4. Liquids & Spray
- 10.5. Others
- 11. By Indication
- 11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 11.1.2. Market Attractiveness Index, By Indication
- 11.2. Opioid Dependence *
- 11.2.1. Introduction
- 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 11.3. Neurological Disorders
- 11.4. Erectile Dysfunction
- 11.5. Nausea and Vomiting
- 11.6. Others
- 12. By Route of Administration
- 12.1. Introduction
- 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 12.1.2. Market Attractiveness Index, By Route of Administration
- 12.2. Sublingual Mucosa *
- 12.2.1. Introduction
- 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 12.3. Buccal Mucosa
- 12.4. Others
- 13. By Distribution Channel
- 13.1. Introduction
- 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 13.1.2. Market Attractiveness Index, By Distribution Channel
- 13.2. Retail Pharmacies*
- 13.2.1. Introduction
- 13.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 13.3. Hospital Pharmacies
- 13.4. Online Pharmacies
- 14. By Region
- 14.1. Introduction
- 14.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 14.1.2. Market Attractiveness Index, By Region
- 14.2. North America
- 14.2.1. Introduction
- 14.2.2. Key Region-Specific Dynamics
- 14.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 14.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 14.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 14.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 14.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 14.2.7.1. The U.S.
- 14.2.7.2. Canada
- 14.2.7.3. Mexico
- 14.3. Europe
- 14.3.1. Introduction
- 14.3.2. Key Region-Specific Dynamics
- 14.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 14.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 14.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 14.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 14.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 14.3.7.1. Germany
- 14.3.7.2. The U.K.
- 14.3.7.3. France
- 14.3.7.4. Italy
- 14.3.7.5. Spain
- 14.3.7.6. Rest of Europe
- 14.4. South America
- 14.4.1. Introduction
- 14.4.2. Key Region-Specific Dynamics
- 14.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 14.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 14.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 14.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 14.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 14.4.7.1. Brazil
- 14.4.7.2. Argentina
- 14.4.7.3. Rest of South America
- 14.5. Asia-Pacific
- 14.5.1. Introduction
- 14.5.2. Key Region-Specific Dynamics
- 14.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 14.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 14.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 14.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 14.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 14.5.7.1. China
- 14.5.7.2. India
- 14.5.7.3. Japan
- 14.5.7.4. Australia
- 14.5.7.5. Rest of Asia-Pacific
- 14.6. Middle East and Africa
- 14.6.1. Introduction
- 14.6.2. Key Region-Specific Dynamics
- 14.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 14.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 14.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 14.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 15. Competitive Landscape
- 15.1. Competitive Scenario
- 15.2. Market Share Analysis
- 15.3. Mergers and Acquisitions Analysis
- 16. Company Profiles
- 16.1. Pfizer Inc.*
- 16.1.1. Company Overview
- 16.1.2. Product Portfolio and Description
- 16.1.3. Financial Overview
- 16.1.4. Key Developments
- 16.2. ZIM Laboratories Limited
- 16.3. Aquestive Therapeutics, Inc
- 16.4. IntelGenx Corp
- 16.5. Indivior PLC
- 16.6. C.L.Pharm Co., Ltd
- 16.7. Seoul Pharmaceuticals
- 16.8. Shilpa Therapeutics
- 16.9. Sunovion Pharmaceuticals, Inc
- 16.10. CURE Pharmaceutical
- 17. Appendix
- 17.1. About Us and Services
- 17.2. Contact Us
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook